Pharmaceuticals

FDA Issues Complete Response Letter to Lykos Therapeutics Regarding Midaphetamine Capsules for the Treatment of Post-Traumatic Stress Disorder

bexib
By bexib 0 Min Read

The complete response letter states that current data on midomaphetamine capsules is insufficient for approval in treating patients with post-traumatic stress disorder.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article The impact of AI adoption on employment: Evidence from US commuter regions
Next Article X faces complaint from Austria over use of data for AI training Reuters – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

How to deal with the insurance implications of renovations
Insurance
Partner country Canada at Hannover Messe 2025
Manufacturing
Visa strengthens AI-powered fraud prevention during holiday shopping worldwide
Fintech
Hannover Messe 2025 – Machine Insider
Manufacturing